FDA approved growth Cerapedics has FDA approved i-FACTOR and PearlMatrix bone graft products, indicating a proven commercial bone repair platform with ongoing IDE study follow-up data. Opportunity: target spine and orthopedic practices needing validated graft options and long-term clinical data to support adoption.

Expansion momentum Significant headcount growth and facility expansion in Colorado point to rapid scale and increasing manufacturing and R&D capacity. Opportunity: engage with operations and procurement leaders to secure supply agreements, CRO/CMO partnerships, and add-on innovations aligned with their scale.

High adoption potential Products are already used in over four million procedures annually, signaling broad clinical familiarity and demand for enhanced bone healing. Opportunity: pursue high-volume hospital networks, spine centers, and trauma programs for expanded installation and education on i-FACTOR and peptide-enhanced grafts.

Data driven sales Recent long-term IDE follow-up data releases reinforce product efficacy and safety signals. Opportunity: leverage robust clinical narratives to support contracting with payers and hospital decision teams emphasizing long-term outcomes and cost-to-fix considerations.

Strategic tech fit Technology stack and digital reach (ads, analytics, identity management) suggest readiness for targeted digital campaigns and account-based selling. Opportunity: deploy ABM programs focused on high-potential orthopedic and spine centers, paired with thought leadership and case studies to accelerate wins.